Modern Vasopressor Therapy of Septic Shock (Review)

Septic shock, as the most severe form of sepsis, is characterized by high mortality reaching 40% despite the use of the most modern standards of diagnosis and treatment. In the thanatogenesis of septic shock, vasoplegia plays a leading role, respectively, and therapy of the condition under discussion involves the use of vasoconstrictors, along with the standard prescription of infusion therapy, antibiotics and symptomatic treatment. The choice of a specific vasoactive drug is a difficult task for a practicing anesthetist, as along with undoubtedly positive properties, vasoconstrictors each have their own spectrum of undesirable side effects, which, of course, must be taken into account when determining treatment tactics.

The aim of review: A comprehensive assessment of the multifactorial effect of various vasoconstrictors on the patient to determine the criteria for choosing the optimal drug (or a combination of drugs) in septic shock.

The search was carried out using PubMed and Scopus databases, the final selection of 89 articles was carried out in accordance with the following criteria: relevance to the topic of this review and the nature of the article — only randomized controlled trials, guidelines and analytical reviews were included in the final analysis.

External and internal mechanisms of vascular tone regulation are considered, including factors produced by endothelium (nitric oxide, prostacyclin, endothelin); vasoactive metabolites and autocoids — signal molecules of local action (serotonin, prostaglandins, thromboxane A2). Accordingly, drugs were analyzed the mechanism of action of which is related to the effect on adrenergic (adrenaline, dopamine, norepinephrine, phenylephrine, dobutamine), vasopressin (vasopressin, terlipressin, selepressin) receptors, synthetic analogues of angiotensin (angiotensin II) and drugs the non-vasopressor effect of which is not linked with the receptor apparatus (methylene blue, levosimendan, hydrocortisone).

Conclusion. The high effectiveness of norepinephrine, its positive hemodynamic effects make the drug under discussion, in many ways, a universal remedy for the relief of septic shock. However, refractory shock may require the introduction of such high doses of norepinephrine that the occurrence of adverse reactions will become practically inevitable. The combined use of adrenergic and ligand V receptors, terlipressin, is intended to prevent these complications. However, to date, there are no clear recommendations on the use of terlipressin in septic shock, which limits its use in clinical practice.

1. Burgdorff A.-M., Bucher M., Schumann J. Vasoplegia in patients with sepsis and septic shock: pathways and mechanisms. J Int Med Res. 2018; 46 (4): 1303–1310. PMID: 29332515, DOI: 10.1177/0300060517743836

2. Rhodes A., Evans L.E., Alhazzani W., Levy M.M., Antonelli M., Ferrer R., Kumar A., Sevransky J.E., Sprung C.L., Nunnally M.E., Rochwerg B, Rubenfeld G.D., Angus D.C., Annane D., Beale R.J., Bellinghan G.J., Bernard G.R., Chiche J.D., Coopersmith C., De Backer D.P., French C.J., Fujishima S., Gerlach H., Hidalgo J.L., Hollenberg S.M., Jones A.E, Karnad D.R., Kleinpell R.M., Koh Y., Lisboa T.C., Machado F.R., Marini J.J., Marshall J.C., Mazuski J.E., McIntyre L.A., McLean A.S., Mehta S., Moreno R.P., Myburgh J., Navalesi P., Nishida O., Osborn T.M., Perner A., Plunkett C.M., Ranieri M., Schorr C.A., Seckel M.A., Seymour C.W., Shieh L., Shukri K.A., Simpson S.Q., Singer M., Thompson B.T., Townsend S.R., Van der Poll T., Vincent J.L., Wiersinga W.J., Zimmerman J.L., Dellinger R.P. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock. 2016. Intensive Care Med. 2017; 43: 304–377. PMID: 28101605, DOI: 10.1007/s00134-017-4683-6.

3. Malbrain M.L., Marik P.E., Witters I., Cordemans C., Kirkpatrick A.W., Roberts D.J., Van Regenmortel N. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. Anaesthesiol Intensive Ther. 2014; 46 (5): 361–380. PMID: 25432556, DOI: 10.5603/AIT.2014.0060

4. Colling K.P., Banton K.L., Beilman G.J. Vasopressors in Sepsis. Surg Infect (Larchmt). 2018; 19 (2): 202–207. PMID: 29336676, DOI: 10.1089/sur.2017.255

5. Sepsis: classification, clinical diagnostic concept and treatment / Edited by academician B.R. Gelfand — 4th edition, revised and revised — Moscow: Medical Information Agency LLC. 2017 [In Russ.] ISBN 978-5-8948-1988-4

6. Lambden S., Creagh-Brown B.C., Hunt J., Summers C., Forni L.G. Definitions and pathophysiology of vasoplegic shock. Critical Care. 2018; 22: 174–181. DOI: 10.1186/s13054-018-2102-1

7. Ilina Ya. Yu., Fot E. V., Izotova N. N., Smetkin A. A., Volkov D. A., Yakovenko E. A., Chernova T. V., Kuzkov V. V., Kirov M. Yu. The relationship of endothelial glycocalyx with hemodynamics and metabolism in patients with septic shock and cardiac surgery with cardiopulmonary bypass. Vestnik anesteziologii i reanimatologii. 2018; 15 (6): 10–19 [In Russ.]. DOI: 10.21292/2078-5658-2018-15-6-10-19

8. Seddon M.D., Chowienczyk P.J., Brett S.E., Casadei B., Shah A.M. Neuronal nitric oxide synthase regulates basal microvascular tone in humans in vivo. Circulation. 2008; 117 (15): 1991–1996. PMID: 18391107, DOI: 10.1161/CIRCULATIONAHA.107.744540

9. Lange M., Enkhbaatar P., Nakano Y., Traber D.L. Role of nitric oxide in shock: the large animal perspective. Front Bioscie. 2009; 14: 1979– 1989. PMID: 19273179, DOI: 10.2741/3357

10. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987; 327 (6122): 524–526. PMID: 3495737, DOI: 10.1038/327524a0

11. Landry D.W., Oliver J.A. The pathogenesis of vasodilatory shock. N Engl J Med. 2001; 345: 588–595. DOI: 10.1056/NEJMra002709

12. Riedo F.X., Munford R.S., Campbell W.B., Reisch J.S., Chien K.R., Gerard R.D. Deacylated lipopolysaccharide inhibits plasminogen activator inhibitor-1, prostacyclin, and prostaglandin E2 induction by lipopolysaccharide but not by tumor necrosis factor-alpha. J Immunol. 1990; 144 (9): 3506–3512. PMID: 2109778

13. Parkington H.C., Coleman H.A., Tare M. Prostacyclin and endothelium dependent hyperpolarization. Pharmacol Res. 2004; 49 (6): 509– 514. PMID: 15026028, DOI: 10.1016/j.phrs.2003.11.012.

14. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999; 79 (4): 1193–1226. PMID: 10508233, DOI: 10.1152/physrev.1999.79.4.1193

15. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332 (6163): 411–415. PMID: 2451132, DOI: 10.1038/332411a0

16. Luscher T.F., Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000; 102 (19): 2434–2440. PMID: 11067800, DOI: 10.1161/01.cir.102.19.2434

17. Ilina Ya.Yu., Fot E.V., Kuzkov V.V., Kirov M.Yu. Sepsis-induced damage to endothelial glycocalyx (literature review). Vestnik intensivnoj terapii imeni A.I. Saltanova. 2019; 2: 32–39 [In Russ.] DOI: 10.21320/1818-474X-2019-2-32-39

18. Yeager M.E., Belchenko D.D., Nguyen C.M., Colvin K.L., Ivy D.D., Stenmark K.R. Endothelin-1, the unfolded protein response, and persistent inflammation: role of pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 2012; 46 (1): 14–22. PMID: 21778413, DOI: 10.1165/rcmb.2010-0506OC.

19. Kimmoun A., Novy E., Auchet T., Ducrocq N., Levy B. Hemodynamic consequences of severe lactic acidosis in shock states: from bench to bedside. Crit Care. 2015; 19: 175–187. PMID: 25887061, DOI: 10.1186/s13054-015-0896-7

20. Russell J.A. Bench-to-bedside review: vasopressin in the management of septic shock. Crit Care. 2011; 15 (4): 226–244. PMID: 21892977, DOI: 10.1186/cc8224

21. Velissaris D., Karamouzos V., Ktenopoulos N., Pierrakos C., Karanikolas M. The use of sodium bicarbonate in the treatment of acidosis in sepsis: a literature update on a long term debate. Crit Care Res Pract. 2015; 2015: 605–830. PMID: 26294968, DOI: 10.1155/2015/605830

22. Förstermann U., Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006; 113 (13): 1708–1714. PMID: 16585403, DOI: 10.1161/CIRCULATIONAHA.105.602532

23. Marik P.E., Khangoora V., Rivera R., Hooper M.H., Catravas J. Hydrocortisone, vitamin C and thiamine for the treatment of severe Sepsis and septic shock: a retrospective before-after study. Chest. 2017; 151 (6): 1229–1238. PMID: 27940189, DOI: 10.1016/j.chest.2016.11.036.

24. Liaudet L., Rosenblatt-Velin N., Pacher P. Role of peroxynitrite in the cardiovascular dysfunction of septic shock. Curr Vasc Pharmacol. 2013; 11 (2): 196–207. PMID: 23506498, DOI: 10.2174/1570161111311020009.

25. Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 2007; 6 (11): 917–935. PMID: 17948022, DOI: 10.1038/nrd2425

26. Koenitzer J.R., Isbell T.S., Patel H.D., Benavides G.A., Dickinson D.A., Patel R.P., Darley-Usmar V.M., Lancaster J.R. Jr., Doeller J.E., Kraus D.W. Hydrogen sulfide mediates vasoactivity in an O 2 -dependent manner. Am J Physiol Heart Circ Physiol. 2007; 292 (4): H1953–60. PMID: 17237242, DOI: 10.1152/ajpheart.01193.2006

27. Ali M.Y., Ping C.Y., Mok Y.Y., Ling L., Whiteman M., Bhatia M., Moore P.K. Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide? Br J Pharmacol. 2006; 149 (6): 625–634. PMID: 17016507, DOI: 10.1038/sj.bjp.0706906

28. Keung E.C., Li Q. Lactate activates ATP-sensitive potassium channels in Guinea pig ventricular myocytes. J Clin Invest. 1991; 88 (5): 1772– 1777. PMID: 1939661, DOI: 10.1172/JCI115497

29. Levy B., Fritz C., Tahon E., Jacquot A., Auchet T., Kimmoun A. Vasoplegia treatments: the past, the present, and the future. Crit Care. 2018; 22 (1): 52–62. PMID: 29486781, DOI: 10.1186/s13054-018-1967-3.

30. Kimmoun A., Ducrocq N., Levy B. Mechanisms of vascular hyporesponsiveness in septic shock. Curr Vasc Pharmacol. 2013; 11: 139–149. PMID: 23506493, DOI: 10.2174/1570161111311020004

31. Ghosh S., Liu M.S. Changes in alpha-adrenergic receptors in dog livers during endotoxic shock. J Surg Res. 1983; 34 (3): 239–245. PMID: 6300552, DOI: 10.1016/0022-4804 (83)90066-5.

32. Barrett L.K, Singer M., Clapp L.H. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med. 2007; 35: 33–40. PMID: 17133186, DOI: 10.1097/01.CCM.0000251127.45385.CD

33. Morales D., Madigan J., Cullinane S., Chen J., Heath M., Oz M., Oliver J.A., Landry D.W. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation. 1999; 100: 226– 229. PMID: 10411844, DOI: 10.1161/01.cir.100.3.226

34. Spink J., Cohen J., Evans T.J. The cytokine responsive vascular smooth muscle cell enhancer of inducible nitric oxide synthase. Activation by nuclear factor-kappa B. J Biol Chem. 1995; 270 (49): 29541–29547. PMID: 7493996, DOI: 10.1074/jbc.270.49.29541

35. Boillot A., Massol J., Maupoil V., Grelier R., Bernard B., Capellier G., Berthelot A., Barale F. Myocardial and vascular adrenergic alterations in a rat model of endotoxin shock: reversal by an antitumor necrosis factor-alpha monoclonal antibody. Crit Care Med. 1997; 25: 504–511. PMID: 9118669, DOI: 10.1097/00003246-199703000-00021

36. Sapicheva Yu.Yu., Lihvancev V.V., Petrovskaya E.L., Lopatin A.F. Tactics of management of patients with sepsis and septic shock in a multispecialty hospital. Moscow: Moscow; 2015. 35 p [In Russ.] ISBN 978-5-98511-299-3

37. Rachoin J.-S. and Dellinger R. Timing of norepinephrine in septic patients: NOT too little too late. Crit Care. 2014; 18 (6): 691–692. PMID: 25672524, DOI: 10.1186/s13054-014-0691-x.

38. Arslantas M.K., Gul F., Kararmaz A., Sungur F., Ayanoglu H.O., Cinel I. Early administration of low dose norepinephrine for the prevention of organ dysfunctions in patients with sepsis. Intensive Care Med Exp. 2015; 3 (1): A417–418. PMCID: PMC4798466, DOI: 10.1186/2197-425X-3-S1-A417-418

39. Dubin A., Lattanzio B., Gatti L. The spectrum of cardiovascular effects of dobutamine — from healthy subjects to septic shock patients. Rev Bras Ter Intensiva. 2017; 29 (4): 490–498. PMID: 29340539, DOI: 10.5935/0103-507X.20170068

40. Avni T., Lador A., Lev S., Leibovici L., Paul M., Grossman A. Vasopressors for the treatment of septic shock: systematic review and metaanalysis. PLoS One. 2015; 10 (8): e0129305. PMID: 26237037, DOI: 10.1371/journal.pone.0129305

41. Myburgh J.A., Higgins A., Jovanovska A., Lipman J., Ramakrishnan N., Santamaria J. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008; 34 (12): 2226–2234. PMID: 18654759, DOI 10.1007/s00134-008-1219-0.

42. Zhou F., Mao Z., Zeng X., Kang H., Liu H., Pan L., Hou P.C. Vasopressors in septic shock: a systematic review and network meta-analysis. Ther Clin Risk Manag. 2015; 11: 1047–1059. PMID: 26203253, DOI: 10.2147/TCRM.S80060

43. Nagendran M., Maruthappu M., Gordon A.C., Gurusamy K.S. Comparative safety and efficacy of vasopressors for mortality in septic shock: A network meta-analysis. J Intensive Care Soc. 2016; 17 (2): 136–145. PMID: 28979478, DOI: 10.1177/1751143715620203

44. De Backer D., Biston P., Devriendt J., Madl C., Chochrad D., Aldecoa C., Brasseur A., Defrance P., Gottignies P., Vincent J.L. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010; 362 (9): 779–789. PMID: 20200382, DOI: 10.1056/NEJMoa0907118

45. Galley H.F. Renal-dose dopamine: will the message now get through? Lancet. 2000; 356 (9248): 2112–2113. PMID: 11191531, DOI: 10.1016/S0140-6736(00)03484-X

46. De Backer D., Aldecoa C., Njimi H., Vincent J.L. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. Crit Care Med. 2012; 40 (3): 725–730. PMID: 22036860, DOI: 10.1097/CCM.0b013e31823778ee

47. Stratton L., Berlin D.A., Arbo J.A. Vasopressors and Inotropes in Sepsis. Emerg Med Clin North Am. 2017; 35 (1): 75–91. PMID: 27908339, DOI: 10.1016/j.emc.2016.09.005.

48. Jain G., Singh D.K. Comparison of phenylephrine and norepinephrine in the management of dopamine-resistant septic shock. Indian J Crit Care Med. 2010; 14 (1): 29–34. PMID: 20606906, DOI: 10.4103/0972-5229.63033.

49. Dmitrieva N.V., Petuhova I.N., Gromova E.G. Sepsis: selected issues of diagnosis and treatment. Moscow: Publishing House ABVpress. 2018: 416p [In Russ.]. ISBN 978-5-903018-55-0

50. Beurton A., Ducrocq N., Auchet. T, Joineau-Groubatch F., Falanga A., Kimmoun A., Girerd N., Fay R., Vanhuyse F., Tran N., Levy B. Beneficial effects of norepinephrine alone on cardiovascular function and tissue oxygenation in a pig model of cardiogenic shock. Shock. 2016; 46 (2): 214–218. PMID: 26849625, DOI: 10.1097/SHK.0000000000000579

51. Khanna A., English S.W., Wang X.S., Ham K., Tumlin J., Szerlip H., Busse L.W., Altaweel L., Albertson T.E., Mackey C., McCurdy M.T., Boldt D.W., Chock S., Young P.J., Krell K., Wunderink R.G., Ostermann M., Murugan R., Gong M.N., Panwar R., Hästbacka J., Favory R., Venkatesh B., Thompson B.T., Bellomo R., Jensen J., Kroll S., Chawla L.S., Tidmarsh G.F., Deane A.M. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017; 377 (5): 419–430. PMID: 28528561, DOI: 10.1056/NEJMoa1704154

52. Bassi E., Park M., Azevedo L.C. Therapeutic strategies for high-dose vasopressor-dependent shock. Crit Care Res Pract. 2013; 2013: 654– 708. PMID: 24151551, DOI: 10.1155/2013/654708

53. Jentzer J.C., Coons J.C., Link C.B., Schmidhofer M. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. J Cardiovasc Pharmacol Ther. 2015; 20 (3): 249–260. PMID: 25432872, DOI: 10.1177/1074248414559838

54. Auchet T., Regnier M.-A., Girerd N., Levy B. Outcome of patients with septic shock and high-dose vasopressor therapy. Ann Intensive Care. 2017; 7: 43–51. PMID: 28425079, DOI: 10.1186/s13613-017-0261-x

55. Shin J.Y., Roh S.G., Lee K.M., Yang K.M. Ischemic Necrosis of Upper Lip, and All Fingers and Toes After Norepinephrine Use. J Craniofac Surg. 2016; 27 (2): 453–454. PMID: 26854781, DOI: 10.1097/SCS.0000000000002463.

56. Cox J., Roche S. Vasopressors and development of pressure ulcers in adult critical care patients. Am J Crit Care. 2015; 24 (6): 501-510. PMID: 26523008, DOI: 10.4037/ajcc2015123

57. Medina-Concepción A., del Cristo Acosta-Ramos M., Pérez-García I., García-Díaz A., Plasencia-Hernández C., Díaz-Melián A., Jiménez-Sosa A. Effect of infused norepinephrine dosage on pressure ulcers in perianesthesia care unit patients: a pilot study. J Perianesth Nurs. 2011; 26 (1): 25–34. PMID: 21276546, DOI: 10.1016/j.jopan.2010.11.002

58. Theaker C., Mannan M., Ives N., Soni N. Risk factors for pressure sores in the critically ill. Anaesthesia. 2000; 55 (3): 221–224. PMID: 10671839, DOI: 10.1046/j.1365-2044.2000.01216.x

59. Yamamura H., Kawazoe Y., Miyamoto K., Yamamoto T., Ohta Y., Morimoto T. Effect of norepinephrine dosage on mortality in patients with septic shock. J Intensive Care. 2018; 6: 12-18. PMID: 29497535, DOI: 10.1186/s40560-018-0280-1

60. Martin C., Medam S., Antonini F., Alingrin J., Haddam M., Meyssignac B., Vigne C., Zieleskiewicz L., Leone M. Norepinephrine: not too much, too long. Shock. 2015; 44 (4): 305–309. PMID: 26125087, DOI: 10.1097/SHK.0000000000000426.

61. Jenkins C.R., Gomersall C.D., Leung P., Joynt G.M. Outcome of patients receiving high dose vasopressor therapy: a retrospective cohort study. Anaesth Intensive Care. 2009; 37 (2): 286–289. PMID: 19400494, DOI: 10.1177/0310057X0903700212.

62. Wu J.Y., Stollings J.L., Wheeler A.P., Semler M.W., Rice T.W. Efficacy and Outcomes After Vasopressin Guideline Implementation in Septic Shock. Ann Pharmacother. 2017; 51 (1) 13–20. PMID: 27630192, DOI: 10.1177/1060028016669163

63. Kozlov I. A., Tyurin I. N., Rautbart S. A. Early hemodynamic predictors of fatal outcome of abdominal sepsis. Vestnik anesteziologii i reanimatologii. 2018; 15 (2): 6–15 [In Russ.]. DOI: 10.21292/2078-5658-2018-15-2-6-15

64. Enrico C., Kanoore Edul V.S., Vazquez A.R., Pein M.C., Pérez de la Hoz R.A., Ince C., Dubin A. Systemic and microcirculatory effects of dobutamine in patients with septic shock. J Crit Care. 2012; 27 (6): 630–638. PMID: 23084135, DOI: 10.1016/j.jcrc.2012.08.002

65. Sato R., Nasu M. A review of sepsis-induced cardiomyopathy. J Intensive Care. 2015; 3: 48–54. PMID: 26566443, DOI: 10.1186/s40560-015-0112-5

66. Marks J.A., Pascual J.L. Selepressin in septic shock: sharpening the VASST effects of vasopressin? Crit Care Med. 2014; 42 (7): 1747–1748. PMID: 24933060, DOI: 10.1097/CCM.0000000000000420.

67. Russell J.A., Fjell C., Hsu J.L., Lee T., Boyd J., Thair S., Singer J., Patterson A.J., Walley K.R. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. Am J Respir Crit Care Med. 2013; 188: 356–364. PMID: 23796235, DOI: 10.1164/rccm.201302-0355OC

68. Dünser M.W., Mayr A.J., Tür A., Pajk W., Barbara F., Knotzer H., Ulmer H., Hasibeder W.R. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine resistant vasodilatory shock: incidence and risk factors. Crit Care Med. 2003; 31 (5): 1394– 1398. PMID: 12771608, DOI: 10.1097/01.CCM.0000059722.94182.79.

69. Patel B.M., Chittock D.R., Russell J.A., Walley K.R. Beneficial affects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002; 96 (3): 576–582. PMID: 11873030, DOI: 10.1097/00000542-200203000-00011

70. Xiao X., Zhang J., Wang Y., Zhou J., Zhu Y., Jiang D., Liu L., Li T. Effects of terlipressin on patients with sepsis via improving tissue blood flow. J Surg Res. 2016; 200 (1): 274–282. PMID: 26253455, DOI: 10.1016/j.jss.2015.07.016

71. Bihari S., Prakash S., Bersten A. Low-dose vasopressin in addition to noradrenaline may lead to faster resolution of organ failure in patients with severe sepsis/septic shock. Anaesth Intensive Care. 2014; 42 (2): 671–674. PMID: 25233186

72. Hammond D.A, Ficek O.A., Painter J.T., McCain K., Cullen J., Brotherton A.L., Kakkera K., Chopra D., Meena N. Prospective, open-label trial of early, concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock. Pharmacotherapy. 2018; 38 (5): 531–538. PMID: 29600824, DOI: 10.1002/phar.2105.

73. Morelli A., Ertmer C., Rehberg S., Lange M., Orecchioni A., Cecchini V., Bachetoni A., D’Alessandro M., Van Aken H., Pietropaoli P., Westphal M. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care. 2009; 13 (4): R130–143. PMID: 19664253, DOI: 10.1186/cc7990

74. Zhou F.H., Song Q. Clinical trials comparing norepinephrine with vasopressin in patients with septic shock: a meta-analysis. Mil Med Res. 2014; 1: 6–12. PMID: 25722864, DOI: 10.1186/2054-9369-1-6

75. Russell J.A., Walley K.R., Singer J., Gordon A.C., Hebert P.C., Cooper D.J., Holmes C.L., Mehta S., Granton J.T., Storms M.M., Cook D.J., Presneill J.J., Ayers D. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008; 358 (9): 877–887. PMID: 18305265, DOI: 10.1056/NEJMoa067373.

76. O’Brien A., Clapp L., Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet. 2002; 359 (9313): 1209–1210. PMID: 11955542, DOI: 10.1016/S0140-6736 (02)08225-9

77. Svoboda P., Scheer P., Kantorova I., Doubek J., Dudra J., Radvan M., Radvanova J. Terlipressin in the treatment of late phase catecholamine-resistant septic shock. Hepato-gastroenterology. 2012; 59 (116): 1043–1047. PMID: 22580654, DOI: 10.5754/hge10550

78. Asfar P., Hauser B., Ivanyi Z., Ehrmann U., Kick J., Albicini M., Vogt J., Wachter U., Bruckner U.B., Radermacher P., Bracht H. Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit Care Med. 2005; 33 (2): 373–380. PMID: 15699842, DOI: 10.1097/01.ccm.0000152253.45901.fb

79. Morelli A., Donati A., Ertmer C., Rehberg S., Kampmeier T., Orecchioni A., Di Russo A., D’Egidio A., Landoni G., Lombrano M.R., Botticelli L., Valentini A., Zangrillo A., Pietropaoli P., Westphal M. Effects of vasopressinergic receptor agonists on sublingual microcirculation in norepinephrine-dependent septic shock. Crit Care. 2011; 15 (5): R217–226. PMID: 21929764, DOI: 10.1186/cc10453

80. Choudhury A., Kedarisetty C.K., Vashishtha C., Saini D., Kumar S., Maiwall R., Sharma M.K., Bhadoria A.S., Kumar G., Joshi Y.K., Sarin S.K. A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int. 2017; 37 (4): 552– 561. PMID: 27633962, DOI: 10.1111/liv.13252.

81. Morelli A., Ertmer C., Lange M., Dunser M., Rehberg S., Van Aken H., Pietropaoli P., Westphal M. Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. Br J Anaesth. 2008; 100 (4): 494–503. PMID: 18308741, DOI: 10.1093/bja/aen017

82. Zhu Y., Huang H., Xi X., Du B. Terlipressin for septic shock patients: a meta-analysis of randomized controlled study. Journal of Intensive Care. 2019; 7: 16–24. DOI: 10.1186/s40560-019-0369-1

83. Russell J.A., Vincent J.L., Kjolbye A.L., Olsson H., Blemings O., Spapen H., Carl P., Laterre P.-F., Grundermar L. Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care. 2017; 21 (1): 213–222. PMID: 28807037. DOI: 10.1186/s13054-017-1798-7.

84. Gutteling J., Armand R.J. Girbes. Vasoactive medication and RCTs: an impossible marriage. ICU Management & Practice. 2018; 18 (3): 164–170.

85. Chawla L.S., Busse L., Brasha-Mitchell E., Davison D., Honig J., Alotaibi Z., Seneff M.G. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014; 18 (5): 534–542. PMID: 25286986, DOI: 10.1186/s13054-014-0534-9

86. Jentzer J.C., Vallabhajosyula S., Khanna A.K., Chawla L.S., Busse L.W., Kashani K.B. Management of Refractory Vasodilatory Shock. Chest. 2018; 154 (2): 416–426 PMID: 29329694, DOI: 10.1016/j.chest.2017.12.021.

87. Kwok E.S., Howes D. Use of methylene blue in sepsis: a systematic review. J Intensive Care Med. 2006; 21: 359–363. PMID: 17095500, DOI: 10.1177/0885066606290671

88. Kirov M.Y., Evgenov O.V., Evgenov N.V., Egorina E.M., Sovershaev M.A., Sveinbjørnsson B., Nedashkovsky E.V., Bjertnaes L.J. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med. 2001; 29: 1860–1867. PMID: 11588440, DOI: 10.1097/00003246-200110000-00002

89. Volkov V.E., Volkov S.V. The role of glucocorticoid hormones and vasopressors in the treatment of septic shock. Acta medica Eurasica. 2018; 4: 1–8 [In Russ.]